1. Home
  2. TECX vs VERV Comparison

TECX vs VERV Comparison

Compare TECX & VERV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • TECX
  • VERV
  • Stock Information
  • Founded
  • TECX 2019
  • VERV 2018
  • Country
  • TECX United States
  • VERV United States
  • Employees
  • TECX N/A
  • VERV N/A
  • Industry
  • TECX
  • VERV Medicinal Chemicals and Botanical Products
  • Sector
  • TECX
  • VERV Health Care
  • Exchange
  • TECX Nasdaq
  • VERV Nasdaq
  • Market Cap
  • TECX 334.4M
  • VERV 384.2M
  • IPO Year
  • TECX 2018
  • VERV 2021
  • Fundamental
  • Price
  • TECX $19.81
  • VERV $11.06
  • Analyst Decision
  • TECX Buy
  • VERV Buy
  • Analyst Count
  • TECX 7
  • VERV 9
  • Target Price
  • TECX $78.67
  • VERV $14.75
  • AVG Volume (30 Days)
  • TECX 156.7K
  • VERV 7.8M
  • Earning Date
  • TECX 08-13-2025
  • VERV 08-07-2025
  • Dividend Yield
  • TECX N/A
  • VERV N/A
  • EPS Growth
  • TECX N/A
  • VERV N/A
  • EPS
  • TECX N/A
  • VERV N/A
  • Revenue
  • TECX N/A
  • VERV $59,613,000.00
  • Revenue This Year
  • TECX N/A
  • VERV $27.75
  • Revenue Next Year
  • TECX N/A
  • VERV N/A
  • P/E Ratio
  • TECX N/A
  • VERV N/A
  • Revenue Growth
  • TECX N/A
  • VERV 271.44
  • 52 Week Low
  • TECX $13.70
  • VERV $2.87
  • 52 Week High
  • TECX $61.07
  • VERV $11.41
  • Technical
  • Relative Strength Index (RSI)
  • TECX 40.56
  • VERV 84.74
  • Support Level
  • TECX $22.13
  • VERV $5.88
  • Resistance Level
  • TECX $25.75
  • VERV $11.41
  • Average True Range (ATR)
  • TECX 1.44
  • VERV 0.49
  • MACD
  • TECX -0.48
  • VERV 0.64
  • Stochastic Oscillator
  • TECX 10.68
  • VERV 95.00

About TECX Tectonic Therapeutic Inc. Common Stock

Tectonic Therapeutic Inc is a biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of GPCRs. Its technology platform called GEODe, Tectonic is focused on developing biologic medicines that overcome the existing challenges of GPCR-targeted drug discovery to modify the course of disease. Company focus on areas of important unmet medical need, often where therapeutic options are poor or nonexistent, and where new medicines have the potential to improve patient quality of life or extend duration of life. Pipeline includes TX000045, Group 2 PH, TX2100: GPCR Antagonist for Hereditary Hemorrhagic Telangiectasia (HHT), Fibrosis.

About VERV Verve Therapeutics Inc.

Verve Therapeutics Inc clinical-stage company developing a new class of genetic medicines for cardiovascular disease, or CVD, with the potential to transform treatment from chronic therapies to single-course gene editing medicines. The current paradigm of chronic care is fragile requiring rigorous patient adherence, extensive healthcare infrastructure, and regular healthcare access, and leaves many patients without adequate care. Its pipelines are PCSK9, ANGPTL3, and LPA. The group has one reportable segment relating to the research and development of gene-editing medicines. The segment derives its current revenues from research and development collaborations.

Share on Social Networks: